Cybin Inc.

Cybin Inc.

201 views6 min read

Cybin Receives Institutional Review Board Approval for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder

Cybin
-- First-in-human Phase 1/2a trial evaluating the proprietary deuterated psilocybin analog CYB003 expected to begin in mid-2022 --TORONTO, June 09, 2022--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to TherapeuticsTM", today announced... Read More...
M & A866 views8 min read

Cybin Acquires DMT Clinical Study from Entheon Biomedical

Cybin
-- Acquisition of largest Phase 1 DMT study conducted to date is expected to accelerate CYB004 program timeline by nine months ---- Phase 1 study evaluating pharmacokinetics/pharmacodynamics of DMT currently underway and will inform clinical path forward --TORONTO, June 07, 2022--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN)... Read More...
79 views7 min read

Cybin Announces Publication in Frontiers in Psychology Journal Introducing EMBARK, an Integrative Model of Psychedelic Therapy

Cybin
TORONTO, June 02, 2022--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics™", is pleased to announce the publication of a peer-reviewed article introducing EMBARK, a model of psychedelic-assisted psychotherapy that integra... Read More...
137 views7 min read

Cybin Submits IND Application to FDA for its Phase 1/2a First-in-Human Trial of CYB003 for the Treatment of Major Depressive Disorder

Cybin
-- CYB003 is the first psilocybin analog to be evaluated in Phase 1/2a development for the treatment of major depressive disorder --TORONTO, May 31, 2022--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing "Psychedelics to TherapeuticsTM", is pleased to an... Read More...
Calendar122 views8 min read

Cybin and Kernel Announce Results from Kernel Flow® Piloting of Feasibility Study Measuring Ketamine’s Effects on the Brain

Cybin
- Preliminary data confirm Flow's ability to successfully measure neuro-effect of ketamine over 10 days -- Results to be presented at PSYCH Symposium taking place in London on May 11, 2022 -LOS ANGELES & TORONTO, May 09, 2022--(BUSINESS WIRE)--Kernel, a leader in non-invasive neuroimaging, and Cybin Inc. (NEO:CYBN) (NYSE American:CYBN... Read More...
Joint Venture369 views7 min read

Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder

Cybin
TORONTO, April 21, 2022--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing "Psychedelics to TherapeuticsTM", today announced that it has partnered with Clinilabs Drug Development Corporation ("Clinilabs"), a global, full-service contract research organiza... Read More...
1363 views6 min read

Cybin Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and Inhaled DMT

Cybin
- Delivery of CYB004 via inhalation showed significant advantages over intravenously administered dimethyltryptamine ("IV DMT") in preclinical studies --- Rapid onset, longer duration of action and similar low variability achieved with single inhalation of CYB004 compared with IV DMT –- Inhaled CYB004 demonstrated more than 40% improved b... Read More...
599 views6 min read

Cybin Announces Initiation of Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain

Cybin
TORONTO, March 31, 2022--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing "Psychedelics to TherapeuticsTM", today announced that the first study visit has been conducted in a Cybin-sponsored feasibility study evaluating Kernel’s quantitative neuroimaging... Read More...
104 views7 min read

Cybin Announces Successful Completion of In Vivo Preclinical Studies for its Deuterated Psilocybin Analog CYB003 Supporting Advancement into Phase 1/2a Clinical Trial

Cybin
-- IND-enabling safety pharmacology and toxicology studies completed in multiple species under GLP guidelines -- On track to submit IND to U.S. FDA in Q2 2022 for expected initiation of Phase 1/2a trial in mid-2022 --TORONTO, March 29, 2022--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceu... Read More...
863 views5 min read

Cybin-Sponsored Feasibility Study Using Kernel Flow Technology Currently Recruiting Participants

Cybin
TORONTO, March 24, 2022--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics™", reports that its Company-sponsored feasibility study using Kernel’s quantitative neuroimaging technology, Kernel Flow, is actively recruiting p... Read More...
59 views4 min read

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Leads Out in Psychedelic-Based Therapeutics Space

Cybin
NEW YORK, March 07, 2022 -- NetworkNewsAudio – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) announces the availability of a broadcast titled, “Psychedelic Therapies Offer Hope for Mental Health.” To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast To view the full editorial, please visit: https://nnw.fm/JeGwq Th... Read More...
41 views4 min read

Institutional Review Board Grants Approval for Cybin-Sponsored Feasibility Study Using Kernel Flow Technology to Measure Psychedelic Effects on the Brain

Cybin
-Enrollment expected to begin in early 2022 - TORONTO, January 11, 2022--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin"), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics™", today announced that an Institutional Review Board ("IRB") has approved a Company-sponsored feasibility study us... Read More...
856 views6 min read

Cybin Announces Additional Adelia Milestone Achievement

Cybin
TORONTO, January 06, 2022--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) ("Cybin" or the "Company"), a biotechnology company focused on psychedelic pharmaceutical therapies, is pleased to announce that Adelia Therapeutics Inc. ("Adelia"), a wholly-controlled subsidiary of Cybin, has achieved the milestone identified as Year ... Read More...
Financials165 views7 min read

Cybin Provides 2021 Year End Summary

Cybin
TORONTO, December 22, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics™" is pleased to provide a year-end summary of its major milestones and key catalysts from 2021 that it believes have positioned the Company for... Read More...
45 views5 min read

Cybin Confirms Scientific Advice Meeting with UK Medical and Healthcare Products Regulatory Agency for Lead Candidate CYB003 for the Treatment of Major Depressive Disorder and Alcohol Use Disorder

Cybin
TORONTO, December 08, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics™" is pleased to announce that it has confirmed a scientific advice meeting with the UK Medical and Healthcare Products Regulatory Agency ("MHRA... Read More...
Financials54 views8 min read

Cybin Inc. Reports its Second Quarter Financial Results and Recent Business Highlights

Cybin
- Company to host conference call at 4:30pm EST today –TORONTO, November 15, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to TherapeuticsTM", today reported unaudited financial results for its second quarter ended September 30... Read More...
CalendarFinancials109 views1 min read

Cybin to Announce Second Quarter FY2021 Financial Results and Business Update on November 15, 2021

Cybin
TORONTO, November 09, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to TherapeuticsTM" today announced that it will report financial results for its second quarter of fiscal 2021 ended September 30, 2021 on Monday, November 15,... Read More...
125 views9 min read

Cybin Announces Positive CYB003 Data Demonstrating Significant Advantages Over Oral Psilocybin for Treatment of Mental Health

Cybin
Comparative CYB003 pre-clinical data on the Company’s deuterated psilocybin analog may have wide-reaching implications for the treatment of Major Depressive Disorder ("MDD") and Alcohol Use Disorder ("AUD") with less patient variability, faster onset of action, shorter duration of effect and improved brain penetrationTORONTO, November 08,... Read More...
192 views7 min read

Cybin Announces Appointment of Dr. Amir Inamdar as Chief Medical Officer for European Operations and Dr. Geoff Varty as the Head of Research and Development

Cybin
Promotion of Certain Members of Management Team and Engagement with a Capital Markets Communications FirmTORONTO, October 01, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, is pleased to announce: the addition of Dr. Ami... Read More...
1426 views11 min read

Cybin Announces Election of Theresa Firestone as Director, Results of Shareholders’ Meeting and Adoption of Shareholder Rights Plan

Cybin
TORONTO, August 16, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) ("Cybin" or the "Company"), a biotechnology company focused on psychedelic pharmaceutical therapies, is pleased to announce that Theresa Firestone has been elected to its board of directors at the Company’s annual and special meeting of shareholders held... Read More...
63 views4 min read

Cybin to Commence Trading on the NYSE American on August 5

Cybin
TORONTO, August 04, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, today announced that its common shares will open for trading on the NYSE American LLC stock exchange ("NYSE American") on August 5, 2021, under the symbol "CYBN... Read More...
52 views5 min read

Cybin Announces Closing of Overnight Marketed Public Offering of Common Shares and Exercise of Over-Allotment Option

Cybin
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESTORONTO, August 03, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (OTCQB: CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, is pleased to announce that it has closed its previously announced over... Read More...
92 views4 min read

Cybin Announces Size and Pricing of Previously Announced Overnight Marketed Public Offering of Common Shares

Cybin
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESTORONTO, July 28, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, announced today the pricing of its previously announced overnight market... Read More...
61 views8 min read

Cybin Announces Positive Pre-Clinical Results With Multiple Proprietary Psychedelic Molecules and Adelia Milestone Achievement

Cybin
TORONTO, June 28, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on psychedelic pharmaceutical therapies, is pleased to announce that Adelia Therapeutics Inc. ("Adelia"), a wholly-controlled subsidiary of Cybin, has achieved certain earn-out milestones for the period ... Read More...
18 views5 min read

Cybin Announces CDN$20 Million Bought Deal Offering

Cybin
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/TORONTO, Jan. 18, 2021 - Cybin Inc. (NEO: CYBN) ("Cybin" or the "Company"), a life sciences company focused on psychedelic pharmaceutical therapies, is pleased to announce that it has entered into an agreement with Canaccord Genuity Corp. ("... Read More...
M & A110 views4 min read

Cybin Announces API Synthesis of Multiple Tryptamine Derivatives Based on the First Milestone Achievement Pursuant to the Adelia Acquisition

Cybin
Cybin Inc. (NEO:CYBN) ("Cybin" or the "Company"), a life sciences company focused on psychedelic therapeutics, is pleased to announce that Adelia Therapeutics Inc. ("Adelia"), a wholly-controlled subsidiary of Cybin, has achieved the earn-out milestones for the period commencing November 15, 2020, as contemplated by the terms of a contrib... Read More...
Joint Venture104 views6 min read

Cybin Partners with Kernel to Leverage its Breakthrough Neuroimaging Technology for Psychedelic Therapeutics

Cybin
HIGHLIGHTSUsing Kernel’s technology, Cybin will be able to quantify brain activity in real time during psychedelic experiences. The absence of this data has been a limitation in the progression of new molecules targeting neurological disorders.Kernel’s technology opens new frontier in psychedelic therapeutics by acquiring longitudinal bra... Read More...
M & A365 views12 min read

CYBIN Signs Definitive Agreement to Acquire Adelia Therapeutics as Part of its Commitment to Strategic Growth

Cybin
Cybin to host conference call today, December 7, 2020, at 5:00 p.m. ETTransaction adds extensive intellectual property portfolio and product pipeline to potentially diversify Cybin’s programs and includes multiple additional indications.Adelia brings a range of technologies related to novel therapeutics, delivery methods, and therapeutic ... Read More...





Make smarter investment strategies
with in-depth news reports

Join our subscribers!